Directorio independiente

Centro Médico Zambrano Hellion

Monterrey. Esta página agrupa registros donde ClinicalTrials.gov publica nombres de sede que coinciden con este centro dentro de las condiciones que monitoreamos.

Perfil informativo no verificado por el centro

Construido a partir de registros públicos; no implica afiliación.

Sin afiliación: BiomedicalResearch.mx no afirma representar a este centro y no garantiza que este listado sea completo. Confirma siempre nombre, dirección, contacto y estatus en el registro oficial.

Variantes de nombre encontradas

  • CENTRO MEDICO ZAMBRANO HELLION ( Site 0711)
  • CENTRO MEDICO ZAMBRANO HELLION-Centro de Cáncer de Mama ( Site 0595)
  • Centro Medico Zambrano Hellion
  • Hospital Zambrano Hellion TecSalud

Estudios detectados

ReclutandoNCT06393374

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Fase 3Merck Sharp & Dohme LLC
Ver registro oficial ↗
ReclutandoNCT06312176

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Fase 3Merck Sharp & Dohme LLC
Ver registro oficial ↗
ReclutandoNCT06790693

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Fase 3Hoffmann-La Roche
Ver registro oficial ↗
ReclutandoNCT07472517

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

Fase 3Boehringer Ingelheim
Ver registro oficial ↗
ReclutandoNCT07195695

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Fase 3Boehringer Ingelheim
Ver registro oficial ↗
ReclutandoNCT07064473

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Fase 3Boehringer Ingelheim
Ver ficha informativa
ReclutandoNCT07567001

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Fase 3Novo Nordisk A/S
Ver ficha informativa